Third quarter 2024 report

31. Oct 2024 | 3 min read

Moss, 31 October 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the third quarter 2024.

 

Highlights

  • Sales of NOK 32.7 million in 3Q24, up 2% versus 3Q23 (5% organic growth). Revenue of NOK 109.5 million YTD 2024 up 12% versus first nine months of 2023 (12% organic growth).
  • EBITDA of NOK 5.0 million in 3Q24 versus NOK 1.2 million in 3Q23. EBITDA of NOK 16.5 million in the first nine months of 2024 versus NOK 4.3 million in the same period last year.
  • Gross margin of 52% (46%) positively influenced by favourable product mix.
  • Cash position of NOK 93.8 million at the end of the quarter compared to NOK 76.4 million at the end of 3Q23. Sales of fCAL® turbo increased by 76% in 3Q24 compared to 3Q23.
  • Bühlmann, Gentian’s exclusive commercial partner for fCAL turbo and fPELA turbo, announced a worldwide collaboration with Beckman Coulter for both products.
  • Sales of Third-party products increased by 50% in 3Q24 compared to 3Q23.
  • A significant milestone was achieved for the NT-proBNP assay with initial clinical evaluation on 220 patient samples in collaboration with leading Norwegian experts in Cardiology, indicating good clinical performance.
  • Gentian was awarded a patent in Europe for a novel NT-proBNP reference method.

 

GDASA interim report 3Q 2024

GDASA 3Q 24 presentation

 

Webcast

The company will present the results today at 09.00 am, followed by a Q&A session. Join the webcast and submit questions via the following link:

https://attendee.gotowebinar.com/register/5878843925420023896

The webcast will be available on the company website after the presentation.

 

IR contact:

Njaal Kind, CFO

njaal.kind@gentian.no

+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Ole Sørlie, Business Controller at Gentian Diagnostics ASA, on 31 October 2024 at 08:00 CET.

 

About Gentian

Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.

You may also read


Feb 05, 2025 - Ole Sørlie

Invitation to presentation of fourth quarter results

Gentian Diagnostics ASA will present its fourth quarter 2024 results on 12 February 2025 at 10.00 CET.

Dec 04, 2024 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics ASA